| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 433 | 340 | 11 |
| Full Text Views | 1 | 1 | 0 |
| PDF Downloads | 2 | 2 | 0 |
Observations on Serological Responses to Cholera Immunization
Virginia Basaca-Sevilla
Virginia Basaca-Sevilla
Bureau of Research and Laboratories, Department of Health, Division of Communicable Disease and Immunology, Walter Reed Army Institute of Research, Manila, Republic of the Philippines
Search for other papers by Virginia Basaca-Sevilla in
Current site
Google Scholar
PubMed
Search for other papers by Virginia Basaca-Sevilla in
Current site
Google Scholar
PubMed
T. P. Pesigan
T. P. Pesigan
Bureau of Research and Laboratories, Department of Health, Division of Communicable Disease and Immunology, Walter Reed Army Institute of Research, Manila, Republic of the Philippines
Search for other papers by T. P. Pesigan in
Current site
Google Scholar
PubMed
Search for other papers by T. P. Pesigan in
Current site
Google Scholar
PubMed
Richard A. Finkelstein
Richard A. Finkelstein
Bureau of Research and Laboratories, Department of Health, Division of Communicable Disease and Immunology, Walter Reed Army Institute of Research, Manila, Republic of the Philippines
Search for other papers by Richard A. Finkelstein in
Current site
Google Scholar
PubMed
Search for other papers by Richard A. Finkelstein in
Current site
Google Scholar
PubMed
Summary
A comparison of the serological responses to several cholera vaccines and vaccine regimens has been conducted in groups of people in the Philippines. Responses to the vaccines and vaccine regimens, as determined by agglutination and vibriocidal antibody titrations, were observed to differ depending on the vaccine and dosage employed. Those vaccines which were most potent in active mouse protection assays elicited the best responses in the human subjects. Single doses of suitable vaccines were found to give nearly 100% serological response in small groups of individuals. Tests on a vaccine composed of El Tor vibrios showed it to be a safe and potent antigen in humans. It is recommended that consideration be given to the inclusion of El Tor vibrios in cholera vaccines for general use, although locally, in outbreaks of El Tor cholera, exclusive use of an El Tor vaccine would seem justified by the results of this investigation.
Author Notes
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 433 | 340 | 11 |
| Full Text Views | 1 | 1 | 0 |
| PDF Downloads | 2 | 2 | 0 |